JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
Human umbilical vein endothelial cells (HUVECs)
Reaction Conditions
0 ~ 10 μM alprostadil
Applications
Alprostadil (1 nM ~ 10 μM; 48 h) concentration-dependently reduced HUVEC proliferation (up to 100% inhibition) in the presence of 20 ng/mL vascular endothelial growth factor (VEGF), with an IC50 of 400 nM. Alprostadil (0.01 ~ 10 μM; 6 h) also inhibited VEGF-induced HUVEC migration in a concentration dependent manner, with an IC50 of 500 nM.
Animal models
Female C57/bl6 mice, 6 ~ 8 weeks of age
Dosage form
20 ng
Administered subcutaneously for 4 days
Alprostadil treatment (20 ng/animal/day; 4 days) significantly inhibited the fibroblast growth factor (FGF)-induced angiogenesis in mice. Alprostadil could be useful for diseases that require anti-angiogenic therapy, such as diabetic retinopathy and solid tumors.
Note
The technical data provided above is for reference only.
References:
1. Cattaneo MG, Pola S, Dehò V, et al. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. British Journal of Pharmacology, 2003, 138(2): 377-385.
